2025-10-19 11:44:20
Introduction: On November 26, 2018, the U.S. Food and Drug Administration granted accelerated approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that have neurotrophic receptor tyrosine kinase (NTRK) gene fusions, no known acquired resistance mutations, have metastasized or where surgical resection may result in severe morbidity, and have no satisfactory alternative treatments or whose cancer has progressed after treatment.